Analysis of several generations of targeted drugs and their technical characteristics

Asciminib (Asciminib) is a new type of targeted drug that belongs to the third generation of BCR-ABL inhibitors. Different from traditional first-generation (such as imatinib) and second-generation (such as dasatinib, nilotinib) tyrosine kinase inhibitors, asinib uses an allosteric inhibition mechanism by binding to the actin-binding pocket of the BCR-ABL protein ( STAMP site) ** to block tyrosine kinase activity instead of directly competing for the ATP binding site, thereby achieving targeted inhibition of drug-resistant mutant strains.

In terms of technical characteristics, asinib can specifically inhibit BCR-ABL tyrosine kinase, especially showing significant activity against common drug-resistant mutant strains (such as T315I mutation). Traditional targeted drugs have limited efficacy in the face of these mutant strains. However, through allosteric site inhibition, asinib can bypass the problem of ATP competitive resistance, improve the success rate of treatment, and provide a new option for patients with refractory or relapsed chronic myelogenous leukemia (CML).

Asnib has been shown to be well tolerated and has relatively controllable side effects in clinical applications. Common adverse reactions include thrombocytopenia, abnormal liver function and mild gastrointestinal symptoms, but compared with first- and second-generation TKIs, the incidence of serious adverse events is lower. In addition, its oral administration method is simple, patient compliance is high, and it is helpful for long-term maintenance of treatment.

In general, as a third-generation BCR-ABL targeted drug, asinib can effectively respond to drug-resistant mutations through an innovative allosteric inhibition mechanism, expanding the treatment options for chronic myelogenous leukemia. Its precise targeting and controllable side effects provide new treatment strategies for clinical practice, while laying the foundation for the development of future combination treatments and personalized programs.

Reference materials:https://www.drugs.com/